stoxline Quote Chart Rank Option Currency Glossary
  
Gyre Therapeutics, Inc. (GYRE)
7.98  0.08 (1.01%)    12-05 16:00
Open: 7.9
High: 8.025
Volume: 76,969
  
Pre. Close: 7.9
Low: 7.76
Market Cap: 725(M)
Technical analysis
2025-12-05 4:48:14 PM
Short term     
Mid term     
Targets 6-month :  9.89 1-year :  11.55
Resists First :  8.47 Second :  9.89
Pivot price 7.75
Supports First :  7.63 Second :  7.11
MAs MA(5) :  7.75 MA(20) :  7.79
MA(100) :  7.67 MA(250) :  0
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  43.2 D(3) :  32.2
RSI RSI(14): 54.9
52-week High :  13.75 Low :  6.11
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ GYRE ] has closed below upper band by 15.8%. Bollinger Bands are 48.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.04 - 8.07 8.07 - 8.1
Low: 7.68 - 7.71 7.71 - 7.75
Close: 7.92 - 7.98 7.98 - 8.04
Company Description

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Headline News

Thu, 04 Dec 2025
Is Gyre Therapeutics Stock Built to Withstand a Pullback? - Trefis

Mon, 01 Dec 2025
How Low Can Gyre Therapeutics Stock Really Go? - Trefis

Thu, 27 Nov 2025
Why Gyre Therapeutics Inc. stock remains on buy lists - Options Play & Verified Momentum Stock Alerts - BỘ NỘI VỤ

Mon, 10 Nov 2025
Is Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE Of 8.6% Concerning? - Yahoo Finance

Fri, 07 Nov 2025
Gyre Therapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview - TradingView

Fri, 07 Nov 2025
Gyre Therapeutics Reports Q3 2025 Financial Results with Revised Revenue Guidance Amid Product Launch Challenges - Quiver Quantitative

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 96 (M)
Shares Float 21 (M)
Held by Insiders 87 (%)
Held by Institutions 3.4 (%)
Shares Short 1,480 (K)
Shares Short P.Month 1,500 (K)
Stock Financials
EPS 0.03
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.12
Profit Margin 6.1 %
Operating Margin 22.6 %
Return on Assets (ttm) 5.2 %
Return on Equity (ttm) 10 %
Qtrly Rev. Growth 19.8 %
Gross Profit (p.s.) 1.06
Sales Per Share 1.11
EBITDA (p.s.) 0.14
Qtrly Earnings Growth 166.1 %
Operating Cash Flow 4 (M)
Levered Free Cash Flow 3 (M)
Stock Valuations
PE Ratio 199.5
PEG Ratio 0
Price to Book value 7.12
Price to Sales 7.16
Price to Cash Flow 198.12
Stock Dividends
Dividend 3.59
Forward Dividend 0
Dividend Yield 45.1%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android